In Brief: ADM Tronics
This article was originally published in The Gray Sheet
ADM Tronics: Plans to make premarket submission this summer for its Sonotron pulsed radio frequency therapeutic device for the treatment of Carpel and Tarsal Tunnel Syndrome. The submission will include data from 50 patients studied at a single site. Preliminary study data show that out of 30 Carpel Tunnel patients treated with Sonotron, 21 show "improvement in either nerve conduction velocity" or "in the obtained amplitudes of response," ADM Tronics says. Results also show decreased pain, improvement in grip and pinch strength and an improvement in function of the affected hand. The device has been available in Italy and Japan since 1994. The Northvale, New Jersey-based firm also plans to pursue marketing clearance of the device for the treatment of osteoarthritis. ADM had submitted a 510(k) for the Sonotron to treat osteoarthritis ("The Gray Sheet" March 20, 1989, I&W-4), but withdrew the application to collect additional data...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.